Skip to main
SCLX
SCLX logo

SCLX Stock Forecast & Price Target

SCLX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scilex Holding's strategic partnerships are anticipated to provide a predictable and diversified revenue stream, which is likely to enhance its financial stability and enable further research and development initiatives. The innovative products such as SP-102 demonstrate a strong efficacy profile and safety measures, setting them apart from existing therapies, thus potentially capturing a significant market share in the non-opioid pain management sector. Additionally, the impending approval for ELYXYB® in Canada is expected to expand the company's market potential, further solidifying Scilex's position in the pain management landscape.

Bears say

Scilex Holding Co faces a negative outlook primarily due to the cautious market perception, resulting in a lower valuation that reflects broader investor sentiment sensitive to economic factors such as interest rate hikes and regulatory challenges. The company's financials are further strained by its association with Sorrento Therapeutics, which has encountered liquidity issues and market volatility, potentially undermining Scilex's efforts to establish itself independently. Additionally, the application of a 30% discount rate in valuation models emphasizes concerns regarding Scilex's clinical pipeline and product commercialization prospects, compounding the bearish sentiment surrounding the stock.

SCLX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scilex Holding Co and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scilex Holding Co (SCLX) Forecast

Analysts have given SCLX a Strong Buy based on their latest research and market trends.

According to 5 analysts, SCLX has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scilex Holding Co (SCLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.